TMS vs. Deep Brain Stimulation: Comparing Brain Stimulation Treatments

Everything you need to know about TMS vs. Deep Brain Stimulation: Comparing Brain Stimulation Treatments — how it works, what it costs, and how to find a provider who actually knows what they're doing.

When first-line treatments fail, patients with severe, treatment-resistant psychiatric and neurological conditions face a more complex decision: which advanced neuromodulation approach is right for them? Transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS) are three brain stimulation therapies, each with distinct profiles of efficacy, invasiveness, risk, and cost. Understanding these differences can help patients and clinicians weigh the options.

Related: TMS vs DBS: Non-Invasive vs Surgical Brain Stimulation · TMS vs. Vagus Nerve Stimulation · TMS vs VNS: Non-Invasive vs Surgical Neuromodulation

What You’ll Learn

• The fundamental differences in invasiveness between TMS, DBS, and VNS
• How each treatment approach works (targeting, mechanism, continuous vs. acute stimulation)
• Response rates and outcomes for each treatment modality
• When to choose each treatment in the step-wise approach to neuromodulation
• Cost and insurance coverage differences

Understanding the Three Approaches

Before comparing outcomes, it is important to understand how these three interventions differ fundamentally in their approach to brain stimulation.

Transcranial magnetic stimulation (TMS) is entirely non-invasive. A magnetic coil is placed against the scalp, and precisely targeted magnetic pulses painlessly penetrate the skull to stimulate the outer layers of the brain. There are no implants, no surgery, and no anesthesia required. TMS is performed in an outpatient setting, and patients can drive themselves home after each session.

Deep brain stimulation (DBS) requires neurosurgery. Electrodes are surgically implanted into specific deep brain structures — for psychiatric applications, the target is typically the ventral capsule/ventral striatum (VC/VS) or the subcallosal cingulate cortex (SCC). These electrodes are connected via wires threaded under the skin to a battery-powered neurostimulator (similar to a cardiac pacemaker) implanted in the chest. The device delivers continuous or intermittent electrical stimulation to the target brain region.

Vagus nerve stimulation (VNS) is a partially invasive approach. An electrical device — similar in size and design to a cardiac pacemaker — is surgically implanted in the chest, with leads wrapped around the left vagus nerve in the neck. The device delivers regular electrical pulses to the vagus nerve, which has extensive connections to brain structures involved in mood regulation, including the locus coeruleus, raphe nuclei, and limbic structures.

Comparing Invasiveness and Risk

The most dramatic difference among these three treatments is their degree of invasiveness:

TMS — Non-invasive, minimal risk:

• No surgery, no implants
• Most common side effects: mild scalp discomfort, headache
• Rare seizure risk (on the order of 1 in 30,000 sessions)
• No anesthesia required
• Treatment course: typically about 36 sessions over 6-9 weeks

DBS — Invasive neurosurgery with significant risks:

• Requires neurosurgery to place electrodes through openings in the skull
• Risks include: intracranial hemorrhage, infection, hardware complications, and stroke
• General anesthesia required for implantation
• The battery eventually needs surgical replacement (non-rechargeable models) or recharging
• Programming and adjustment requires multiple follow-up visits
• Magnetic resonance imaging (MRI) has significant restrictions after implantation

VNS — Invasive but less so than DBS:

• Requires surgery to implant pulse generator in chest and attach leads to the vagus nerve
• Risks include: surgical site infection, hoarseness, voice changes, cough, throat pain, and rare but serious risks including nerve damage
• The device operates continuously (or in intermittent cycles) after implantation
• MRI restrictions apply

Because of its lower risk, TMS is generally considered before surgical options for patients who are candidates for it. DBS and VNS are generally considered only for patients with severe, chronic, treatment-resistant illness after multiple other treatments.

Clinical Outcomes: What the Evidence Shows

TMS for treatment-resistant depression (TRD):

• Response rates range from roughly 30% in sham-controlled trials to about 50-60% in real-world studies (response means a 50% or greater reduction in symptoms)
• Remission rates range from about 14% in the sham-controlled OPT-TMS trial to about 37% in a real-world study of 307 patients
• Often used alongside medication and psychotherapy
• FDA-cleared for TRD (failed at least one medication trial)

DBS for treatment-resistant depression:

• Early open-label studies of subcallosal cingulate DBS reported high response rates, but the sham-controlled BROADEN trial was stopped after an interim futility analysis and did not show a benefit over sham at 6 months
• DBS is not FDA-approved for depression; it is used in research settings. (A humanitarian device exemption exists for DBS in severe OCD.)
• Long-term durability data are limited to small studies

VNS for treatment-resistant depression:

• The 10-week sham-controlled phase of the pivotal trial did not show a significant benefit over sham; longer open-label follow-up and registry data reported response rates that rose over time, but these lack a control group
• FDA-approved (PMA, 2005) as adjunctive treatment for long-term or recurrent treatment-resistant depression in adults; Medicare’s national coverage is limited to clinical trials
• Benefits, when they occur, tend to develop gradually over months

The Role of Targeting and Mechanism

An important conceptual distinction among these approaches is the nature of the stimulation:

TMS provides targeted, acute modulation of specific cortical regions and their connected networks. It is highly focal — the clinician selects a specific brain target and delivers a specific pattern of stimulation. The effects are dynamic and reversible, and dosing can be adjusted between sessions.

DBS provides continuous, high-frequency electrical stimulation of deep brain structures. The stimulation affects all neurons and axons within its field, producing both therapeutic effects and potentially unwanted side effects depending on the target and settings. DBS essentially creates a reversible, adjustable “lesion” in the stimulated circuit.

VNS operates through a fundamentally different mechanism — rather than directly stimulating the brain, it activates the vagus nerve, which has diffuse projections to brainstem nuclei that, in turn, project widely throughout the cortex and limbic system. The effects of VNS are modulatory and develop gradually over months of stimulation.

Cost Comparison

Cost is a significant practical consideration for patients and healthcare systems:

TMS:

• A course typically costs thousands of dollars without insurance; many insurers and Medicare cover it when criteria are met
• No surgical costs or implanted device

DBS:

• Surgical implantation, the device, and long-term programming are far more costly than a TMS course
• Medicare and some private insurers cover DBS for Parkinson’s disease; coverage for psychiatric uses is limited

VNS:

• Device implantation is a surgical procedure with substantial cost
• Insurance coverage for depression is limited

When to Choose Each Treatment

Treatment of treatment-resistant depression is often approached in steps, though there is no single universal algorithm:

Step 1 — TMS: For patients with TRD who have failed at least one medication trial, TMS is typically the first advanced neuromodulation option considered. Its favorable safety profile, non-invasive nature, and FDA clearance for TRD make it a common first neuromodulation option.

Step 2 — If TMS fails — Consider ECT: For some patients with severe, acute TRD — such as those with psychotic features or acute suicidality — electroconvulsive therapy (ECT) may be the most effective option, despite its cognitive side effects.

Step 3 — If TMS and ECT are inadequate — VNS or DBS: These are considered for the most treatment-resistant patients, usually in specialized centers. VNS is FDA-approved for depression; DBS is investigational for it.

A Complementary Landscape

Importantly, these treatments are not mutually exclusive. A patient may respond well to TMS initially, require maintenance TMS later, and — if severe relapse occurs — be evaluated for device-based neuromodulation. The neuromodulation landscape is not a competition but rather a continuum of options, each suited to different levels of treatment resistance and clinical need.

For patients at any point in this journey, understanding the available options — their risks, benefits, mechanisms, and costs — empowers informed decision-making and better advocacy for their own care.

Related reading

• TMS for Multiple Sclerosis: Addressing Fatigue, Depression, and Cognitive Impairment
• What TMS Actually Feels Like: A Session-by-Session Guide
• How to Prepare for Your First TMS Session
• Preparing for Your First TMS Session: A Practical Walkthrough
• TMS for anxiety
• TMS for Treatment-Resistant Depression: What Patients Need to Know